Hosted on MSN8h
Oppenheimer Upgrades BioMarin Pharmaceutical (BMRN)
Fintel reports that on February 24, 2025, Oppenheimer upgraded their outlook for BioMarin Pharmaceutical (NasdaqGS:BMRN) from ...
BioMarin (BMRN) is an Incredible Growth Stock: 3 Reasons Why
Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great ...
BioMarin Pharmaceutical (NASDAQ:BMRN) Upgraded to Outperform at Oppenheimer
Oppenheimer upgraded shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from a market perform rating to an outperform rating in a research note published on Monday morning, MarketBeat ...
Does BioMarin (BMRN) Have the Potential to Rally 40.54% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 40.5% in BioMarin (BMRN). While the effectiveness of this highly sought-after metric is questionable, the ...
stocknews12h
3 Pharmaceutical Stocks With Blockbuster Drug Potential
The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...
BioMarin upgraded to Outperform from Perform at Oppenheimer
Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target Discover the Best Stocks and Maximize Your Portfolio: ...
Oppenheimer upgrades BioMarin with stage set for increasing interest
Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target BioMarin reported strong Q4 results and Oppenheimer ...